Currently out of the existing stock ratings of Andrew Tsai, 30 are a BUY (90.91%), 3 are a HOLD (9.09%).

Andrew Tsai

Work Performance Price Targets & Ratings Chart

Analyst Andrew Tsai, currently employed at JEFFERIES, carries an average stock price target met ratio of 41.21% that have a potential upside of 25.35% achieved within 118 days.

Andrew Tsai’s has documented 75 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 24-Jul-2025.

Wall Street Analyst Andrew Tsai

Analyst best performing recommendations are on ATHA (ATHIRA PHARMA ).
The best stock recommendation documented was for ATHA (ATHIRA PHARMA ) at 6/23/2022. The price target of $32 was fulfilled within 8 days with a profit of $4.5 (16.36%) receiving and performance score of 20.45.

Average potential price target upside

of $113.05 (75.84%) on ATHA (ATHIRA PHARMA ).
of $27.92 (69.83%) on ITCI (INTRACELLULAR TH).
of $13.07 (59.27%) on XENE (XENON PHARMACEUTICALS).

ATHA Athira Pharma ITCI Intracellular Th XENE Xenon Pharmaceuticals ATAI ATAI Life Sciences BV SAGE Sage Therapeutic VTGN VistaGen Therapeutics MRNS Marinus Pharmaceuticals RLMD Relmada Therapeutics RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics VIGL Vigil Neuroscience

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Graig Suvannavejh (MIZUHO)